Renal cell carcinoma (RCC) is one of the most common solid tumors in adults highly resistant to conventional therapies. The expression profile of a number of miRNAs correlates with RCC response to chemotherapeutic agents.
To identify the association of tumor miRNAs expression with neoadjuvant treatment response in patients with RCC.
We analyzed the expression levels of tumor miR-99b, -144, -155, -210, -222, -302а, -377 in 93 RCC patients who received pazopanib or sunitinib in neoadjuvant regimen using RT-PCR. RNU48 was used as a reference miRNA.
The levels of expression of miR-99b and -377 are associated with the RCC response to pazopanib, and microRNA-210 and -377 to sunitinib. The characteristic expression profile of miR-99b, -144, -222, -377, and miR-302a determined in 90% of cases was delineated in pazopanib responders as opposed to nonresponders. Similarly, the characteristic expression profile of miR-210, -222, -302a and -377 was suggested for sunitinib responders.
Levels of miR-99b, -210 and -377 expression in RCC tumor tissue might be used as a basis for future predictive panel intended for the assessment of the sensitivity to the regimens of neoadjuvant RCC treatment.
Experimental oncology. 2021 Jun [Epub]
Yu V Vitruk, S L Semko, O A Voylenko, M V Pikul, T V Borikun, T V Zadvornyi, T M Yalovenko, E O Stakhovsky, O V Rossylna
National Cancer Institute, Ministry of Health of Ukraine, Kyiv 03022, Ukraine., R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NASU, Kyiv 03022, Ukraine., Clinic for Personalized Diagnostics and Therapy Design "Oncotheranostics", Kyiv 03022, Ukraine.